Formulation and Evaluation of Silver Nanoparticles Floating Tablets for The Treatment of Polycystic Ovarian Syndrome

Background: Floating tablets enhance drug bioavailability by prolonging gastric residence time. This study investigates the formulation of floating tablets containing silver nanoparticles (AgNPs), focusing on excipient compatibility, preparation methods, and in vitro performance. Methods: Silver nanoparticles, HPMC, PVP, lactose, sodium bicarbonate, magnesium stearate, talc, and ethanol were used to formulate floating tablets. Pre-formulation studies assessed melting point, IR spectra, and physical parameters (angle of repose, bulk density, tapped density, Hausner’s ratio). Compatibility was evaluated by IR spectroscopy. Granulation and compression were followed by evaluations of weight variation, hardness, friability, floating lag time, and dissolution in pH 1.2 buffer at 37°C over 24 hours. Results: Pre-formulation studies showed good flow properties and compressibility. Compatibility studies indicated no significant interactions between drug and excipients. Floating lag time ranged from 30 to 240 seconds, with floating times of 6-9 hours. SNs5 formulation released 80.3% of the drug by 24 hours. Other physical parameters, including hardness and friability, were within acceptable limits. Discussion: The floating tablets exhibited good mechanical strength and controlled drug release. Variations in hardness and friability were due to differences in polymer ratios. The presence of silver nanoparticles did not affect tablet integrity or release. The dissolution studies showed a sustained release, indicating potential benefits in extended drug delivery. Conclusion: The floating tablets containing silver nanoparticles successfully achieved controlled release and prolonged gastric residence time. This formulation has the potential to enhance bioavailability and support targeted therapies using silver nanoparticles.